Natco Pharma Ltd.

₹815.35

-3.3 (-0.4%)

NATCOPHARM Share Price

Pharmaceuticals & Biotechnology

As on September 11, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 14,624 Cr

P/E Ratio10.29

Dividend Yield0.31 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	824.87	Bearish
10-DMA	832.52	Bearish
20-DMA	854.26	Bearish
50-DMA	904.97	Bearish
100-DMA	963.57	Bearish
200-DMA	945.17	Bearish

Historical Performance

1 Year

-3.9%

3 Years

0.3%

5 Years

-16.8%

10 Years

22.2%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Net Sales	40,783	44,295	39,988	27,071	19,448
Total Expenditure	26,418	22,357	22,474	17,954	16,813
Other Income	2,976	3,567	1,281	1,285	990
Operating Profit	17,341	25,505	18,795	10,402	3,625
Interest	367	239	192	145	177
Depreciation	2,066	2,352	1,868	1,638	1,426
Profit Before Tax	14,908	22,914	16,735	8,619	2,022
Consolidated Net Profit	14,185	18,854	13,883	7,153	1,700
Adjusted EPS	79	105	78	39	9

Compounded Sales Growth

10 Years:31.4

5 Years:14.7

3 Years:8.5

TTM:-1.6

Compounded Profit Growth

10 Years:55.3

5 Years:26.3

3 Years:14.7

TTM:-5.5

Stock Price CAGR

10 Years:2.4

5 Years:-3.5

3 Years:-1.8

TTM:-5.4

Return on Equity

10 Years:27.9

5 Years:9.3

3 Years:77.6

last year:79.2

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Share Capital	358	358	358	365	365
Total Reserves	91,853	75,712	58,173	48,373	42,237
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	-609	249	610	1,005	1,351
Other Current Liabilities	6,145	2,386	2,389	2,273	1,267
Short Term Borrowings	3,064	2,731	3,632	1,650	4,040
Total Liabilities	1,08,411	85,807	68,869	56,574	51,091
Capital Work in Progress	2,937	2,254	1,373	643	1,295
Long Term Loans & Advances	1,008	738	1,127	783	720
Currents Investments	5,782	3,208	4,435	3,050	2,037
Short Term Loans and Advances	10,311	6,257	6,382	4,856	6,062
Total Current Assets	50,523	52,700	40,235	30,003	24,867
Total Assets	1,08,411	85,807	68,869	56,574	51,091
Adjusted Book Value	515	425	327	267	233

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a moderate PE of 10.29, suggesting fair valuation relative to earnings.
Over the last three years, the stock delivered a weak 3-year price CAGR of -1.8%, indicating poor shareholder returns.
The stock carries a beta of 1.1, indicating volatility broadly in line with the market.
In the last financial year, the company reported an EBITDA of ₹17341 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹40783 million, indicating a large and established business.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 957658

No. of Shares: 1175 (Approx)

Performance:-4.2%

-42342

NIFTY Performance: -6.8%

1 day Top Gainers